

**Amendments to the Claims:**

This listing of claims will replace all previous versions and listings of claims in the application:

1.-6. (canceled)

7. (currently amended) ~~The method of Claim 4 wherein said antagonist is A method of treating an inflammatory disorder in a mammal, comprising administering to said mammal an effective amount of an immunoadhesin comprising an extracellular domain sequence of the polypeptide of SEQ ID NO: 32.~~

8. (currently amended) The method of Claim 7 wherein said immunoadhesin comprises a ~~STIgMA~~ said extracellular domain sequence fused to an immunoglobulin constant region sequence.

9. (previously presented) The method of Claim 8 wherein said extracellular domain sequence is essentially free of transmembrane domain sequences.

10. (previously presented) The method of Claim 9 wherein said immunoglobulin is an IgG.

11. (previously presented) The method of Claim 10 wherein said IgG is IgG1 or IgG3.

12. (previously presented) The method of Claim 2 wherein the inflammatory disorder is selected from the group consisting of: inflammatory bowel disease; systemic lupus erythematosus; rheumatoid arthritis; juvenile chronic arthritis; spondyloarthropathies; systemic sclerosis, for example, scleroderma; idiopathic inflammatory myopathies for example, dermatomyositis, polymyositis; Sjögren's syndrome; systemic vasculitis; sarcoidosis; autoimmune hemolytic anemia for example, immune pancytopenia, paroxysmal nocturnal hemoglobinuria; autoimmune thrombocytopenia, for example, idiopathic thrombocytopenic purpura, immune-mediated thrombocytopenia; thyroiditis, for example, Grave's disease, Hashimoto's thyroiditis, juvenile lymphocytic thyroiditis, atrophic thyroiditis; diabetes mellitus, immune-mediated renal

disease, for example, glomerulonephritis, tubulointerstitial nephritis; demyelinating diseases of the central and peripheral nervous systems such as multiple sclerosis, idiopathic polyneuropathy; hepatobiliary diseases such as infectious hepatitis such as hepatitis A, B, C, D, E and other nonhepatotropic viruses; autoimmune chronic active hepatitis; primary biliary cirrhosis; granulomatous hepatitis; and sclerosing cholangitis; inflammatory and fibrotic lung diseases (e.g., cystic fibrosis); gluten-sensitive enteropathy; Whipple's disease; autoimmune or immune-mediated skin diseases including bullous skin diseases, erythema multiforme and contact dermatitis, psoriasis; allergic diseases of the lung such as eosinophilic pneumonia, idiopathic pulmonary fibrosis and hypersensitivity pneumonitis, transplantation associated diseases including graft rejection and graft-versus host disease.

13. (previously presented) The method of Claim 12 wherein said inflammatory disorder is rheumatoid arthritis.
14. (previously presented) The method of Claim 12 wherein said mammal is human.
15. (previously presented) The method of Claim 13 wherein said mammal is human.
- 16-39. (canceled)